This is the third randomized trial in recent years to show that a proton-pump inhibitor (PPI) conferred no clinically important improvement in asthma control for patients with both asthma and GERD.

412 adults with inadequately controlled asthma were randomized to receive the proton-pump inhibitor (PPI) esomeprazole (Nexium; 40 mg twice daily) or placebo. Reasoning that patients who have ...